Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squi...(report on Form 10-K quarterly reports on...)

Date:4/24/2008

report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company and Conference Call Information

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

There will be a conference call on April 24, 2008 at 10:30 a.m. (EDT) during which company executives will address inquiries from investors and analysts. Investors and the general public are invited to listen to a live web cast of the call at http://www.bms.com/ir or by dialing 913-312-0861, confirmation code 4556649. Materials related to the call will be available at the same website prior to the call.

ABILIFY(R) is the trademark of Otsuka Pharmaceutical Co., Ltd.

ATRIPLA(TM) is a trademark of both Bristol-Myers Squibb Co. and Gilead Sciences, Inc.
AVAPRO(R), AVALIDE(R) and PLAVIX(R) are trademarks of sanofi-aventis

Erbitux(R) is a trademark of ImClone Systems Incorporated

BRISTOL-MYERS SQUIBB COMPANY

NET SALES FROM CONTINUING OPERATIONS

FOR THE THREE MONTHS ENDED MARCH 31, 2008 AND 2007

(Unaudited, dollars in millions)

BY OPERATING SEGMENT: Three Months Ended March 31,

2008 2007 % Change

Pharmaceuticals $4,188 $3,457 21%

Nutritionals 703 606 16%

ConvaTec 290 254 14%

Net Sales $5,181 $4,317 20%

FOR SELECTED PRODUCTS:

'/>"/>

SOURCE Bristol-Myers Squibb Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related biology technology :

1. Genzyme Reports Strong First-Quarter Growth
2. Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
3. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
4. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
5. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
6. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
7. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
8. Genoptix Reports Strong Financial Results For Third Quarter 2007
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Cephalon Announces Strong Third Quarter Financial Results
11. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues